Novelion Therapeutics Appoints New Senior VP and CFO

Novelion Therapeutics (NASDAQ:NVLN) announced the appointment of Michael Price as senior vice president and CFO.
As quoted in the press release:

Gregory Perry has resigned as CFO of Novelion to pursue other opportunities, and will remain with the Company until December 31, 2017 to enable an effective transition.

Chairman of the Board of Directors Jason Aryeh said, “We are very pleased to welcome Michael, a skilled executive with deep financial acumen, and extensive experience in organizations with both research and development and global commercial capabilities. We look forward to his contributions as we focus on maximizing the value and growth potential of our current product portfolio and creating the ability to invest in our growth. With a new leadership team that includes the recent additions of Chief Operating Officer Jeffrey Hackman and Head of Research and Development Murray Stewart, we believe we are well positioned to execute on these goals.

“Also, we would like to recognize Greg’s leadership, and the significant progress we made during his tenure as CFO to stabilize and cleanse many of the issues inherited in 2015. Thanks in large part to those accomplishments, we believe meaningful value creation opportunities are ahead.”

Click here to read the full press release.

Source: globenewswire.com